User-defined outline with 11 sections.

Executive Summary

GreenWell Medicinal Cannabis at a Glance

GreenWell Medicinal Cannabis (Private) Limited is a Zimbabwe-registered medicinal cannabis farming and processing business based on a 20-hectare farm outside Marondera, Mashonaland East. We are building a controlled-environment supply platform for licensed domestic buyers and export markets, with our first commercial output focused on high-CBD and balanced THC/CBD dried flower and a phased move into crude extract.

Our business exists to solve the supply problem that keeps recurring across African medicinal cannabis sourcing: inconsistent quality, unreliable supply, and weak traceability. We are answering that gap with GAP-compliant cultivation, batch-level documentation, third-party lab testing, and pharmaceutical-grade post-harvest handling.

At a glance

• Legal entity: GreenWell Medicinal Cannabis (Private) Limited
• Location: Marondera, Mashonaland East, Zimbabwe
• Initial production footprint: 5 hectares of greenhouse and shade-net cultivation
• Target customers: Licensed pharmaceutical distributors, processors, wholesalers, and export buyers
• Core products: Medicinal cannabis flower and crude extract
• Year 1 revenue: USD 5,040,000
• Year 1 EBITDA: USD 924,000
• Year 1 net income: USD 640,490
• Break-even timing: Month 1 within Year 1
• Year 5 revenue target: USD 14,537,931

We are not building a consumer brand. We are building a regulated B2B supply business that sells traceable, lab-tested medicinal cannabis to buyers who need repeatable procurement, not speculative harvest volumes. That distinction matters because the market rewards consistency, documentation, and compliance more than land size alone.

Our commercial model is anchored by In Year, our founder and managing director, who brings commercial horticulture and export agriculture experience in Zimbabwe, including contract farming management for export vegetables. Day-to-day finance and compliance are led by Drew Martinez, a chartered accountant with 10 years of agribusiness and export finance experience. Cultivation is overseen by Sam Patel, an agronomist with greenhouse horticulture experience and two years in a cannabis operation in Lesotho. Processing and quality are handled by Jamie Okafor, a food scientist with GMP experience in herbal extracts and pharmaceuticals, while sales and export relationships are managed by Skyler Park, who has 8 years in regional commodity export and established networks with South African and EU buyers.

Our product strategy is deliberately focused. We are targeting licensed buyers that typically purchase 50 kg to 500 kg lots and require certificates of analysis, clean chain-of-custody records, and reliable shipment scheduling. By combining greenhouse control with strict batch traceability, we are building a supplier profile that is suitable for regulated buyers in Zimbabwe, South Africa, the EU, and Israel.

The market opportunity is real and specific. We estimate at least 25 to 40 serious buyers in Southern Africa and 50+ buyers in Europe and Israel already sourcing from the continent. GreenWell Medicinal Cannabis is positioned to win a manageable share of that market by serving 8 to 12 repeat buyers over the next three years, which is enough to absorb our planned capacity and support stable, contract-led growth.

Our financial model shows a business that is already commercially viable at launch. We forecast USD 5,040,000 in revenue in Year 1, rising to USD 9,000,000 in Year 2 and USD 14,537,931 in Year 5. Gross margin remains steady at 32.1%, and Year 1 operating cash flow is USD 413,490, which supports the debt and working capital structure without relying on unrealistic assumptions.

:::reassure Why this matters to investors and lenders
GreenWell Medicinal Cannabis is built for disciplined scale, not speculative growth.

• The farm is already defined and located near logistics infrastructure.
• The customer base is licensed and repeat-oriented.
• The product mix is aligned to documented demand.
• The operating model is cash-generative from Year 1.
  :::

Funding We Are Raising and How It Fits the Business

We are seeking USD 650,000 in total project funding to complete infrastructure, compliance, and working capital for launch and early scaling. The funding stack is structured as USD 200,000 in equity capital and USD 450,000 in debt principal, which gives GreenWell the balance sheet strength to build properly while preserving long-term ownership value.

That capital will support the controlled cultivation platform, security systems, processing capability, genetics, licensing, and working capital needed to reach commercial output quickly. The financial model shows Year 1 gross profit of USD 1,620,000, EBITDA of USD 924,000, and net income of USD 640,490, so the business is capable of servicing debt and generating reinvestable cash once production is live.

:::warning Key investor reality
The biggest risks are execution risks, not market-size risks.

• Licensing and export approvals must remain current.
• Crop performance must stay consistent under controlled conditions.
• Security and traceability must be maintained at all times.
• Buyer onboarding must remain tied to documented compliance and COAs.
  :::

Headline Growth Outlook

The growth path is straightforward. We are starting with 150 kg of saleable dried flower per month in Year 1, scaling to 300 kg per month equivalent in Year 2, and adding crude extract in Year 3. By Year 5, we target a more mature export platform with revenue of USD 14,537,931 and net income of USD 2,794,335.

This is a medicinal cannabis farming business, but it is also a documentation business, a quality business, and a buyer-trust business. GreenWell Medicinal Cannabis is built to win because we combine agricultural control with regulatory discipline and a sales model centered on long-term off-take relationships.

The result is a Zimbabwean medicinal cannabis company with a clear site, named leadership, licensed buyer focus, and a forecast that supports investor confidence from the first operating cycle.

Company Description

GreenWell Medicinal Cannabis (Private) Limited

GreenWell Medicinal Cannabis (Private) Limited is a Zimbabwe-registered private limited company established to produce compliant medicinal cannabis flower and crude extract for licensed domestic buyers and export markets. We operate from a 20-hectare farm just outside Marondera in Mashonaland East, with initial commercial cultivation set across 5 hectares of greenhouse and shade-net structures.

Our business is built around controlled-environment farming, batch traceability, and pharmaceutical-grade handling from cultivation through drying, curing, packaging, and dispatch. We are positioning GreenWell as a reliable Zimbabwean supplier to licensed pharmaceutical distributors, extractors, and wholesalers that require consistent quality, lab-tested output, and documentation aligned to GACP, EU-GMP pathways, and South African regulatory expectations.

The business we are building

GreenWell Medicinal Cannabis exists to solve a practical supply problem in the regional cannabis trade. Many buyers sourcing from Africa face irregular batch quality, weak traceability, inconsistent moisture control, and delivery risk. We are structured to address that gap with disciplined production, documented processes, and a quality-first operating model.

Our core products are:

• High-CBD medicinal cannabis flower
• Balanced THC/CBD medicinal cannabis flower
• Crude extract for licensed processors and formulators
• Contract-growing and strain-customisation support for approved buyers

We do not trade as a consumer brand. We serve regulated business customers who buy in bulk, expect certificates of analysis, and need repeat supply that can support downstream manufacturing or resale under licence.

Legal structure and regulatory position

GreenWell Medicinal Cannabis (Private) Limited is incorporated under Zimbabwean law as a Private Limited company. We are operating within the medicinal cannabis regulatory framework and hold, or are in the final approval stage for, the required cultivation and export licences.

That legal footing matters to our customers and finance partners because the market is licence-led, documentation-heavy, and highly sensitive to compliance. Our model is designed for visible recordkeeping, lot-level controls, and auditable production records from seed to shipment.

:::warning Regulatory discipline is part of our commercial model

• Every batch is handled under documented traceability.
• Every sale is limited to licensed buyers.
• Every shipment is supported by quality and compliance records.
• Non-compliant production is treated as a direct business risk, not an administrative detail.
  :::

Ownership and leadership

The company is led by In Year, the founder and managing director of GreenWell Medicinal Cannabis (Private) Limited. In Year has a background in commercial horticulture and export agriculture in Zimbabwe, including prior management of contract farming schemes for export vegetables, and brings practical experience in compliance, logistics, and quality control.

Our finance and compliance function is led by Drew Martinez, a chartered accountant with 10 years of agribusiness and export finance experience, including EU-compliant supply chain exposure. Cultivation is overseen by Sam Patel, an agronomist with experience in greenhouse horticulture and two years in a cannabis operation in Lesotho. Processing and quality are managed by Jamie Okafor, a food scientist with GMP experience in herbal extracts and pharmaceuticals. Sales and export relationships are handled by Skyler Park, who brings 8 years in regional commodity export and established networks with South African and EU buyers.

The ownership structure reflects our commitment to founder-led control with external capital support. The founder and family investors have committed USD 200,000 in equity, and the balance of the capital stack is being raised through USD 450,000 in debt financing and/or strategic investment to complete the build-out and working capital requirements.

Location and operating footprint

Our Marondera location gives us access to agricultural land, transport links toward Harare, and a practical base for controlled-environment production. We selected this site because medicinal cannabis requires both security and proximity to logistics infrastructure, while remaining separated enough from dense urban activity to support a controlled farm environment.

The operating footprint includes greenhouse production, shade-net cultivation, drying and curing space, secure packaging areas, and a basic extraction-ready processing area. We are designing the site for movement control, lot segregation, and secure handling so that output can be scaled without losing compliance discipline.

What GreenWell sells and who buys it

GreenWell sells bulk medicinal cannabis flower and crude extract to licensed business buyers. Our target customers are pharmaceutical manufacturers, cannabis extractors, wholesalers, and other approved medicinal supply-chain participants in Zimbabwe, South Africa, the EU, and Israel.

These customers do not buy based on appearance alone. They buy based on:

• batch consistency
• moisture and potency control
• third-party lab results
• traceability documentation
• secure and reliable delivery schedules
• licenced origin and export readiness

That is why our production model is deliberately smaller and more intensively managed than high-volume commodity farms. We are prioritising commercial reliability over undifferentiated scale.

Mission, positioning, and long-term intent

Our mission is to build Zimbabwe’s most trusted medicinal cannabis supplier for regulated B2B markets, using controlled-environment cultivation, disciplined compliance, and transparent quality standards. We want GreenWell to be known for predictable batches, clean documentation, and professional buyer relationships.

Our strategic position is straightforward. We compete against farms that may have acreage but lack consistency, and against larger regional suppliers that often struggle with transparent communication and batch-level accountability. GreenWell is designed to win through control, compliance, and responsiveness.

:::reassure Why our model is attractive to serious buyers

• We focus on repeatable batches rather than speculative production.
• We operate with named technical responsibility across cultivation, quality, finance, and sales.
• We build for exportable standards from the start.
• We are structured to support long-term contracts, not one-off opportunistic sales.
  :::

Growth trajectory and business maturity

In Year 1, GreenWell is targeting steady commercial output of 150 kg of dried medicinal cannabis per month, supported by signed off-take agreements and a documented compliance trail. By Year 2, we plan to expand effective capacity to 300 kg per month through yield optimisation and one additional greenhouse block.

By Year 3, we intend to integrate basic extraction and add crude oil sales as a secondary revenue stream. By Years 4 to 5, we aim to move toward higher-value strains and EU-GMP aligned processing, with capacity rising to 400 kg to 450 kg per month equivalent and a stronger export profile.

The company is therefore not a speculative start-up. It is a structured, licence-based agricultural and processing business with a defined market, a defined farm location, named operational leadership, and a clear path from controlled cultivation to value-added medicinal cannabis supply.

🔒 Continues in the full version

The remaining 9 sections of this document cover:

• Products and Services
• Market Analysis
• Competitive Analysis
• SWOT Analysis
• Marketing and Sales Strategy
• Management and Organization
• Operating Plan
• Financial Plan and Projections
• Funding Request

The full document is available below — click through for complete access.